Plenary Session

This BONUS episode is the recording of a lecture given on June 18, 2020 as part of Stanford's METRICS International Forum. METRICS stands for Meta-Research Innovation Center at Stanford University. This lecture is geared towards a broad audience and aims to provide a general sense of current cancer research. The lecture is titled "Cancer Meta-Research 101". Back us on Patreon! www.patreon.com/plen...

This week we respond to some listener feedback from Dr. Christopher Booth and use it to talk about how to be the best hematologist-oncologist. We also discuss the SADAL study on Selinexor for patients with relapsed refractory diffuse large B-cell lymphoma, as published in The Lancet Haematology. Finally, we interview Drs. Eva Katsoulakis and Michael Kelley on their recent paper out in the Journal...

This week we briefly cover updates on the RECOVERY trial before segueing into an interview with Dr. Andrae Vandross on Twitter (specifically #medtwitter), academic discussions, and changing your career to find your calling. RECOVERY: www.recoverytrial.net/ Malignant audiobook: www.audible.com/pd/B08864KFHW/?so…ACX0_195112_rh_us Back us on Patreon! www.patreon.com/plenarysession

This week's episode is jam-packed with topics! We talk about the RECOVERY trial, the U.S. clinical trial infrastructure, event-free survival (EFS) and cost of care in acute myeloid leukemia, how long it takes to write papers in academic medicine, threats to public health officials, and the application to medicine of Dr. Raj Chetty's work in economics. Finally, we interview this week's special gues...

This week we tackle the topic of tucatinib in HER2-positive breast cancer with brain metastases. We also interview Dr. Cailin O'Connor of the University of California Irvine on her research on misinformation and disinformation. We discuss her recent article in the Boston Review, titled "Hydroxychloroquine and the Political Polarization of Science", as well as her extensive body of work. HER2CLIMB:...

We start this week's episode by covering some recent research: After thoroughly critiquing the recent randomized trial of hydroxychloroquine for postexposure prophylaxis for COVID-19, we then discuss the five abstracts selected for plenary sessions at the recent virtual meeting of the American Society of Clinical Oncology. We transition from there to a Question from a Medical Student with Audrey T...

This week we talk all things COVID-19! We start with an in-depth Classical Hematology Chat with Dr. Sven Olson and Dr. Joseph Shatzel of Oregon Health & Science University on thrombosis and anticoagulation in COVID-19, touching on a number of recent studies. We then turn to a conversation with Dr. Walid Gellad of the University of Pittsburgh on new pharmaceutical treatments for COVID-19. Tang et a...

This week we discuss why being open-minded enough to agree partially with someone - instead of taking an all-or-nothing approach to a discourse - is important. We also sit down with epidemiologist Dr. Daniel Morgan of the University of Maryland School of Medicine to critique the public health policy concerning COVID-19 transmission. Back us on Patreon! www.patreon.com/plenarysession

This week we have an announcement -- the audiobook of "Malignant: How Bad Policy and Bad Evidence Harm People with Cancer", written and narrated by our host Vinay Prasad, is available now on Amazon, iTunes, and Audible! We also have an in-depth journal club for you on the findings of the PROfound trial as published in a new paper out in the New England Journal of Medicine titled "Olaparib for Meta...

This BONUS lecture was a talk given to the Hematology/Oncology fellows at Oregon Health & Science University. It's part three of a three-part series on clinical trials. Back us on Patreon! www.patreon.com/plenarysession

This week's topic is all things COVID-19 -- we discuss the viral scandal of British epidemiologist Neil Ferguson's actions and how it reflects (or doesn't) on his work, we talk about the nuances of how to end lockdowns, and we bring back Dr. Benjamin Singer, a pulmonary and critical care physician at Northwestern University, to address updates in the ICU management of COVID-19. Invisible Pandemic:...

This week we begin with a monologue on the recent controversy surrounding Dr. John Ioannidis's published opinions on the COVID-19 pandemic. We end with a group discussion with Oregon Health & Science University's Hematology/Oncology fellows on our host's, Vinay Prasad's, new book "Malignant: How Bad Policy and Bad Evidence Harm People with Cancer." Expressing different views on COVID-19: https://w...

This week we have a BONUS episode for you! As a teaser to the forthcoming audiobook of "Malignant: How Bad Policy and Bad Evidence Harm People with Cancer" by Dr. Vinay Prasad (our host), Audrey Tran and Ian Straehley have set the introduction of the book to music they composed and arranged themselves. You can buy the print version of Malignant from Amazon: https://www.amazon.com/Malignant-Policy-...

This week we start with an in-depth monologue on various new developments surrounding COVID-19, specifically the new study in NEJM on the compassionate use of remdesivir as well as the CDC's advice for the general public to wear cloth masks. We end with an interview with Dr. Ameet Sarpatwari of Harvard Medical School on how to create a more effective pharmaceutical system, the CREATES Act of 2019,...

This week we have a far-reaching monologue on COVID-19 and how people are reacting to the public health recommendations concerning COVID-19 (such as cancelling conferences and school, maintaining 6+ feet of distance, wearing cloth masks). We end with an insightful interview with Dr. Venk Murthy on polygenic risk score and, at the end, a bit about how the world of science is failing to combat hype....

This week we discuss several recent articles on the novel coronavirus (SARS-CoV-2) and COVID-19, specifically Dr. Siddhartha Mukherjee's article on the history and science of humanity's history with viruses, Dr. Ezekiel Emanuel's essay on how to fairly allocate dwindling medical resources during this global pandemic, and Dr. John Ioannidis's article on the "evidence fiasco" that has been our respo...

This week we discuss management of COVID-19 in the intensive care unit with Dr. Benjamin Singer, a pulmonary and critical care physician at Northwestern University. We discuss medications, PPE, ventilators, and more! Back us on Patreon! www.patreon.com/plenarysession

This bonus episode is an interview from March 16, 2020 with Dr. John Townes, the Interim Head for the Division of Infectious Disease and the Medical Director for Infection Prevention and Control here at Oregon Health & Science University. We talk about the novel coronavirus and how healthcare professionals are responding to the COVID-19 pandemic, with a focus on Oregon. Back us on Patreon! www.pat...

This week we discuss two recent papers -- one we praise, one we condemn -- and then we turn to a question of the week with medical student Audrey Tran on self-improvement and "refining conviction". The first paper is titled "Patient Experience Captured by Quality-of-Life Measurement in Oncology Clinical Trials" and the second is titled "Overall survival in patients with pancreatic cancer receiving...

This BONUS lecture was a talk given to the Hematology/Oncology fellows here at Oregon Health & Science University. It's part two of a three-part series on clinical trials. This talk is on clinical trial design, specifically crossover and control arms. Back us on Patreon! www.patreon.com/plenarysession

This week we revisit BEACON! The authors of the BEACON study have responded to the Letter to the Editor our host Dr. Vinay Prasad submitted to the New England Journal of Medicine, and we share our thoughts on what they said. We then turn to the FDA's recent approval of neratinib in combination with capecitabine for HER2-positive breast cancer, based on the phase III NALA trial. Finally, we intervi...

Our guest this week is Dr. Michael Hengartner of the Zurich University of Applied Sciences. We interview him on his work studying the long-term consequences and effectiveness of newer-generation antidepressants - specifically focusing on selective serotonin reuptake inhibitors (SSRIs). Back us on Patreon! www.patreon.com/plenarysession

We start this episode by diving deep into KEYNOTE-048, the randomized, open-label, phase 3 study of pembrolizumab alone or with chemotherapy v.s. cetuximab with chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck (HNSCC). We transition from there to a continued discussion on careerism in academia and how the motivation behind publishing papers should always stem f...

We have a full slate for you this week! We discuss careerism in medicine, presenting abstracts at conferences, #MedTwitter, and Dr. Califf's opinions on the K-Index. We conclude the episode with our first-ever Classical Hematology Chat, featuring our host Dr. Vinay Prasad, Dr. Sven Olson, and Dr. Joseph Shatzel. The chat is on sickle cell disease. "A Perspective on the K-Index": doi.org/10.1016/j....

This week we discuss the concept of "thought leaders" and we examine the conclusions about volume CT screening for lung cancer from the NELSON trial. We end with an interview with Dr. Sam Rubinstein, a hematology/oncology fellow at Vanderbilt University Medical Center, on his new paper published in JAMA Network Open titled "Indication of Measures of Uncertainty for Statistical Significance in Abst...